Business Context and Reporting Period
This Form 8-K Current Report was filed by Cormedix Inc. on October 4, 2021. The filing reports significant changes in executive leadership and corporate governance effective October 4, 2021.
Key Financial Metrics
This filing is a current report regarding personnel changes and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- CEO Departure: Khoso Baluch retired as Chief Executive Officer and resigned from the Board of Directors effective October 4, 2021. The departure was mutual and not due to any disagreement with the Company.
- Executive Vice President Departure: John L. Armstrong, Jr. retired as Executive Vice President, Technical Operations, effective October 4, 2021.
- Interim Leadership: Matthew David, M.D., the current Chief Financial Officer, was appointed Interim Chief Executive Officer effective immediately.
- Operational Oversight: Phoebe Mounts, Ph.D., Esq., EVP, General Counsel, and Head of Regulatory, Compliance, and Legal, assumed direct authority over the Technical Operations group, including consultants addressing deficiencies at a third-party manufacturing facility.
Guidance, Outlook, and Management Commentary
- Succession Plan: The Board has initiated a search process with a leading executive search firm to identify a permanent Chief Executive Officer.
- Transition Support: Mr. Baluch will serve in an advisory capacity to facilitate a smooth transition.
- Separation Terms: Both departing executives entered into separation agreements providing severance payments and benefits equivalent to a termination without cause. Both received retirement treatment allowing vested stock options to remain exercisable for up to three years post-separation. The Company agreed to reimburse legal fees for both executives.
- Covenants: Both executives remain bound by confidentiality, non-solicitation, and non-competition covenants.
Investor Verification Checklist
- Verify the timeline for the appointment of a permanent CEO.
- Review the status of the third-party manufacturing facility deficiencies mentioned under the new oversight of Phoebe Mounts.
- Examine the specific terms of the separation agreements (Exhibits 10.1 referenced in prior filings) to understand the exact financial impact of severance payments.
- Monitor future filings for the results of the executive search and any further changes to the Board of Directors.